Drugs / Vidutolimod
Vidutolimod
also known as
CMP-001 · CYT003 · CYT003-QbG10 · QbG10 · Vidutolimod component of cmp-001 cpg-a oligodeoxynucleotide tlr9 agonist
Other / unclassified targets TLR9 via activation
Trials 20 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03507699 | Dec 2018 → Aug 2021 | metastasis from malignant tumor of colon | Sheba Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT03438318 | Mar 2018 → Dec 2019 | non-small cell lung carcinoma | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT03084640 | May 2017 → Jul 2021 | melanoma | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02680184 | Apr 2016 → Dec 2022 | melanoma | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04387071 | Apr 2021 → Dec 2022 | high grade malignant neoplasm, pancreatic adenocarcinoma | University of Southern California | Terminated | No outcome recorded |
| Phase 1/2 | NCT03983668 | Jan 2020 → Aug 2024 | lymphoma | Umar Farooq | Terminated | No outcome recorded |
| Phase 1/2 | NCT02554812 | Nov 2015 → Mar 2023 | cancer of unknown primary site | Pfizer | Terminated | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT05445609 | Jun 2023 → Jun 2027 | prostate adenocarcinoma | Emory University | Suspended | No outcome recorded |
| Phase 2 | NCT04916002 | Nov 2021 → Oct 2024 | cutaneous neuroendocrine carcinoma, non-small cell lung carcinoma, oropharynx squamous cell carcinoma, skin basal cell carcinoma +2 | Regeneron Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT04708418 | Oct 2021 → Dec 2026 expected | cutaneous melanoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04807192 | Apr 2021 → Dec 2025 overdue | triple-negative breast carcinoma | Centre Hospitalier Universitaire Vaudois | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04698187 | Mar 2021 → Feb 2024 | metastatic melanoma | Regeneron Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT04633278 | Jan 2021 → Jan 2024 | head and neck squamous cell carcinoma | Regeneron Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT04401995 | Sep 2020 → Aug 2024 | melanoma | Diwakar Davar | Completed | No outcome recorded |
| Phase 2 | NCT03618641 | Aug 2018 → Aug 2020 | lymph node cancer, melanoma | Diwakar Davar | Completed | No outcome recorded |
| Phase 2 | NCT02087644 | May 2014 | asthma | Cytos Biotechnology AG | Withdrawn | No outcome recorded |
| Phase 2 | NCT01673672 | Nov 2012 → May 2014 | chronic asthma | Cytos Biotechnology AG | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04695977 | Feb 2021 → Jul 2024 | metastatic melanoma | Regeneron Pharmaceuticals | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05059522 | Sep 2021 → Dec 2026 expected | non-small cell lung carcinoma, ovarian cancer, urothelial carcinoma | Pfizer | Active not recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT06063746 | — | refractory malignant neoplasm | Regeneron Pharmaceuticals | No longer available | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vidutolimod | “CMP-001 (vidutolimod, CYT003, QbG10) has already been shown to increase CD8+ T cell intratumoral infiltration in early clinical data, and ongoing data of a phase Ib clinical...” NCT04807192 ↗5“Vidutolimod (CMP-001) is a Toll-like receptor 9 (TLR9) agonist, with the ability to generate tumor-targeted T cells capable of killing a tumor both locally and systemically in...” NCT05445609 ↗ “Vidutolimod, a CpG-A TLR9 agonist, was investigated in a phase 1b study (CMP-001-003; ClinicalTrials.gov, NCT03438318) in combination with atezolizumab with and without...” PMID 36925644 ↗ Oct 2022 |
| Known as | CMP-001 | “patients receiving either neoadjuvant Vidutolimod (CMP-001)/nivolumab or neoadjuvant nivolumab.” NCT04401995 ↗ |
| Known as | CYT003 | “CMP-001 (vidutolimod, CYT003, QbG10) has already been shown to increase CD8+ T cell intratumoral infiltration in early clinical data, and ongoing data of a phase Ib clinical...” NCT04807192 ↗ |
| Known as | CYT003-QbG10 | “A Randomized, Placebo-Controlled, Phase IIb Study of CYT003-QbG10 (CYT003), a TLR9 Agonist, in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on...” NCT02087644 ↗ |
| Known as | QbG10 | “CMP-001 (vidutolimod, CYT003, QbG10) has already been shown to increase CD8+ T cell intratumoral infiltration in early clinical data, and ongoing data of a phase Ib clinical...” NCT04807192 ↗ |
| Known as | Vidutolimod component of cmp-001 cpg-a oligodeoxynucleotide tlr9 agonist | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315003 ↗ |
| Action | Activate | “a TLR9-agonist” NCT01673672 ↗ |
| Modality | Other / unclassified | “Vidutolimod, a CpG-A TLR9 agonist” PMID 36925644 ↗ Oct 2022 |
| Route | Subcutaneous | “7 subcutaneous injections, weekly/biweekly within 10 weeks” NCT01673672 ↗ |
| Target | TLR9 | “a TLR9-agonist” NCT01673672 ↗ |